| Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma L Santo, T Hideshima, AL Kung, JC Tseng, D Tamang, M Yang, M Jarpe, ... Blood, The Journal of the American Society of Hematology 119 (11), 2579-2589, 2012 | 664 | 2012 |
| Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma N Mimura, M Fulciniti, G Gorgun, YT Tai, D Cirstea, L Santo, Y Hu, ... Blood, The Journal of the American Society of Hematology 119 (24), 5772-5781, 2012 | 451 | 2012 |
| Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma M Ladetto, G Pagliano, S Ferrero, F Cavallo, D Drandi, L Santo, C Crippa, ... Journal of Clinical Oncology 28 (12), 2077-2084, 2010 | 340 | 2010 |
| The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors EA Nelson, SR Walker, E Weisberg, M Bar-Natan, R Barrett, LB Gashin, ... Blood, The Journal of the American Society of Hematology 117 (12), 3421-3429, 2011 | 329 | 2011 |
| A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma G Görgün, E Calabrese, T Hideshima, J Ecsedy, G Perrone, M Mani, ... Blood, The Journal of the American Society of Hematology 115 (25), 5202-5213, 2010 | 314 | 2010 |
| Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease S Vallet, S Mukherjee, N Vaghela, T Hideshima, M Fulciniti, S Pozzi, ... Proceedings of the National Academy of Sciences 107 (11), 5124-5129, 2010 | 305 | 2010 |
| PI3K/p110δ is a novel therapeutic target in multiple myeloma H Ikeda, T Hideshima, M Fulciniti, G Perrone, N Miura, H Yasui, Y Okawa, ... Blood, The Journal of the American Society of Hematology 116 (9), 1460-1468, 2010 | 274 | 2010 |
| Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma G Görgün, E Calabrese, E Soydan, T Hideshima, G Perrone, M Bandi, ... Blood, The Journal of the American Society of Hematology 116 (17), 3227-3237, 2010 | 252 | 2010 |
| The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo H Ikeda, T Hideshima, M Fulciniti, RJ Lutz, H Yasui, Y Okawa, T Kiziltepe, ... Clinical Cancer Research 15 (12), 4028-4037, 2009 | 243 | 2009 |
| Cyclin dependent kinases in cancer: potential for therapeutic intervention M Canavese, L Santo, N Raje Cancer biology & therapy 13 (7), 451-457, 2012 | 200 | 2012 |
| Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple … D Cirstea, T Hideshima, S Rodig, L Santo, S Pozzi, S Vallet, H Ikeda, ... Molecular cancer therapeutics 9 (4), 963-975, 2010 | 194 | 2010 |
| A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function S Vallet, S Pozzi, K Patel, N Vaghela, MT Fulciniti, P Veiby, T Hideshima, ... Leukemia 25 (7), 1174-1181, 2011 | 172 | 2011 |
| Targeting cyclin-dependent kinases and cell cycle progression in human cancers L Santo, KT Siu, N Raje Seminars in oncology 42 (6), 788-800, 2015 | 162 | 2015 |
| AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition L Santo, S Vallet, T Hideshima, D Cirstea, H Ikeda, S Pozzi, K Patel, ... Oncogene 29 (16), 2325-2336, 2010 | 154 | 2010 |
| Ascorbic acid inhibits antitumor activity of bortezomib in vivo G Perrone, T Hideshima, H Ikeda, Y Okawa, E Calabrese, G Gorgun, ... Leukemia 23 (9), 1679-1686, 2009 | 153 | 2009 |
| Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death Y Mishima, L Santo, H Eda, D Cirstea, N Nemani, AJ Yee, E O'Donnell, ... British journal of haematology 169 (3), 423-434, 2015 | 142 | 2015 |
| High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties S Pozzi, S Vallet, S Mukherjee, D Cirstea, N Vaghela, L Santo, E Rosen, ... Clinical Cancer Research 15 (18), 5829-5839, 2009 | 137 | 2009 |
| Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome M Ladetto, S Vallet, A Trojan, M Dell'Aquila, L Monitillo, R Rosato, L Santo, ... Blood 105 (12), 4784-4791, 2005 | 114 | 2005 |
| The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival H Ohguchi, T Hideshima, MK Bhasin, GT Gorgun, L Santo, M Cea, ... Nature communications 7 (1), 10258, 2016 | 105 | 2016 |
| Regulation of sclerostin expression in multiple myeloma by Dkk‐1: a potential therapeutic strategy for myeloma bone disease H Eda, L Santo, MN Wein, DZ Hu, DD Cirstea, N Nemani, YT Tai, ... Journal of Bone and Mineral Research 31 (6), 1225-1234, 2016 | 94 | 2016 |
Güllü Topal GörgünExecutive Director, Sr.Global Project Leader, Hematology AstraZeneca, Waltham, MA, USA在 astrazeneca.com 的电子邮件经过验证
